Concepts (195)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Zinc Oxide | 1 | 2021 | 69 | 0.85 | Why? |
| Silver | 1 | 2021 | 327 | 0.70 | Why? |
| Influenza A Virus, H5N1 Subtype | 1 | 2021 | 492 | 0.67 | Why? |
| Gold | 1 | 2021 | 592 | 0.64 | Why? |
| AIDS-Related Opportunistic Infections | 2 | 2017 | 260 | 0.44 | Why? |
| Dysentery, Amebic | 2 | 2012 | 6 | 0.42 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2021 | 2984 | 0.31 | Why? |
| HIV Infections | 11 | 2021 | 11620 | 0.29 | Why? |
| Anti-Retroviral Agents | 4 | 2017 | 1099 | 0.28 | Why? |
| Furin | 2 | 2021 | 1054 | 0.26 | Why? |
| Food Additives | 1 | 2021 | 27 | 0.23 | Why? |
| Entamoeba histolytica | 2 | 2012 | 22 | 0.22 | Why? |
| Fluoresceins | 1 | 2020 | 46 | 0.22 | Why? |
| Amino Acid Chloromethyl Ketones | 1 | 2020 | 62 | 0.22 | Why? |
| Nanocomposites | 1 | 2021 | 62 | 0.22 | Why? |
| Protease Inhibitors | 4 | 2021 | 3630 | 0.21 | Why? |
| HIV Seropositivity | 2 | 2019 | 320 | 0.20 | Why? |
| Giant Cells | 1 | 2021 | 334 | 0.19 | Why? |
| Apolipoprotein A-V | 1 | 2018 | 6 | 0.19 | Why? |
| Lipoprotein Lipase | 1 | 2018 | 12 | 0.19 | Why? |
| Maintenance Chemotherapy | 1 | 2019 | 133 | 0.18 | Why? |
| Antiretroviral Therapy, Highly Active | 2 | 2019 | 952 | 0.18 | Why? |
| Rilpivirine | 1 | 2018 | 65 | 0.18 | Why? |
| Lignans | 1 | 2018 | 41 | 0.18 | Why? |
| Benzoxazines | 1 | 2017 | 103 | 0.17 | Why? |
| Mycobacterium avium-intracellulare Infection | 1 | 2017 | 59 | 0.17 | Why? |
| HIV Integrase Inhibitors | 1 | 2019 | 173 | 0.17 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2019 | 309 | 0.17 | Why? |
| Taiwan | 6 | 2021 | 2556 | 0.16 | Why? |
| Oseltamivir | 1 | 2021 | 583 | 0.16 | Why? |
| Hepatitis A Vaccines | 1 | 2017 | 52 | 0.16 | Why? |
| Drug Resistance, Viral | 2 | 2021 | 1083 | 0.16 | Why? |
| Hypertriglyceridemia | 1 | 2018 | 90 | 0.16 | Why? |
| Biphenyl Compounds | 1 | 2018 | 249 | 0.16 | Why? |
| Particle Size | 1 | 2021 | 1052 | 0.15 | Why? |
| Drug Substitution | 1 | 2019 | 385 | 0.15 | Why? |
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 275 | 0.15 | Why? |
| Lamivudine | 1 | 2016 | 210 | 0.15 | Why? |
| Triglycerides | 1 | 2018 | 478 | 0.14 | Why? |
| Hepatitis B | 2 | 2016 | 888 | 0.14 | Why? |
| Hepatitis C | 2 | 2019 | 1514 | 0.14 | Why? |
| Metal Nanoparticles | 1 | 2021 | 771 | 0.13 | Why? |
| Entamoebiasis | 1 | 2012 | 10 | 0.13 | Why? |
| HEK293 Cells | 3 | 2021 | 8394 | 0.13 | Why? |
| Tenofovir | 1 | 2016 | 449 | 0.13 | Why? |
| Peptide Hydrolases | 1 | 2021 | 1269 | 0.13 | Why? |
| Endemic Diseases | 1 | 2016 | 480 | 0.12 | Why? |
| Infectious Disease Incubation Period | 1 | 2020 | 1033 | 0.12 | Why? |
| Virus Internalization | 2 | 2021 | 7921 | 0.12 | Why? |
| Spike Glycoprotein, Coronavirus | 5 | 2021 | 37182 | 0.11 | Why? |
| Hepatitis B virus | 2 | 2016 | 882 | 0.11 | Why? |
| Sexual and Gender Minorities | 1 | 2019 | 1019 | 0.09 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2017 | 1138 | 0.09 | Why? |
| Antigens, Protozoan | 1 | 2008 | 121 | 0.09 | Why? |
| Hemagglutination Tests | 1 | 2008 | 124 | 0.09 | Why? |
| Interferon-gamma | 1 | 2017 | 2711 | 0.08 | Why? |
| Respiratory System | 1 | 2020 | 3213 | 0.08 | Why? |
| Vero Cells | 5 | 2021 | 14117 | 0.08 | Why? |
| Peptide Fragments | 1 | 2017 | 2075 | 0.08 | Why? |
| Autoantibodies | 1 | 2017 | 2094 | 0.08 | Why? |
| Genetic Variation | 1 | 2020 | 3919 | 0.08 | Why? |
| Antiviral Agents | 5 | 2021 | 41703 | 0.07 | Why? |
| Anti-HIV Agents | 1 | 2018 | 2209 | 0.07 | Why? |
| Sulfonamides | 1 | 2014 | 1294 | 0.07 | Why? |
| Exanthema | 1 | 2014 | 1097 | 0.07 | Why? |
| Protein Binding | 1 | 2021 | 11430 | 0.07 | Why? |
| Costs and Cost Analysis | 1 | 2008 | 694 | 0.06 | Why? |
| Homosexuality, Male | 1 | 2012 | 1158 | 0.06 | Why? |
| Phylogeny | 2 | 2020 | 13341 | 0.06 | Why? |
| Virus Replication | 2 | 2021 | 14331 | 0.06 | Why? |
| Kinetics | 2 | 2021 | 3238 | 0.06 | Why? |
| Drug Repositioning | 1 | 2020 | 5683 | 0.06 | Why? |
| Genome, Viral | 2 | 2021 | 13157 | 0.06 | Why? |
| Nelfinavir | 1 | 2020 | 187 | 0.05 | Why? |
| Humans | 28 | 2021 | 930598 | 0.05 | Why? |
| Animals | 7 | 2021 | 78931 | 0.05 | Why? |
| Genotype | 3 | 2019 | 4697 | 0.05 | Why? |
| Seroconversion | 2 | 2020 | 2515 | 0.05 | Why? |
| Antibodies, Viral | 3 | 2021 | 51949 | 0.05 | Why? |
| Multivariate Analysis | 3 | 2017 | 5440 | 0.05 | Why? |
| Genetic Fitness | 1 | 2021 | 339 | 0.05 | Why? |
| Seroepidemiologic Studies | 2 | 2021 | 10017 | 0.05 | Why? |
| Magnolia | 1 | 2018 | 3 | 0.05 | Why? |
| Substrate Specificity | 1 | 2021 | 639 | 0.05 | Why? |
| 3T3-L1 Cells | 1 | 2018 | 29 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.05 | Why? |
| RNA, Viral | 4 | 2020 | 32276 | 0.05 | Why? |
| Patient Acceptance of Health Care | 1 | 2017 | 5002 | 0.05 | Why? |
| Cytochrome P-450 CYP2B6 | 1 | 2017 | 12 | 0.05 | Why? |
| Gene Knock-In Techniques | 1 | 2018 | 124 | 0.04 | Why? |
| Alkynes | 1 | 2017 | 98 | 0.04 | Why? |
| Cost-Benefit Analysis | 1 | 2008 | 2259 | 0.04 | Why? |
| Hepatitis A Antibodies | 1 | 2017 | 18 | 0.04 | Why? |
| Inhibitory Concentration 50 | 1 | 2020 | 907 | 0.04 | Why? |
| CD4 Lymphocyte Count | 2 | 2017 | 1517 | 0.04 | Why? |
| Adult | 13 | 2021 | 244371 | 0.04 | Why? |
| Sexuality | 1 | 2017 | 85 | 0.04 | Why? |
| Heterozygote | 1 | 2018 | 249 | 0.04 | Why? |
| Sustained Virologic Response | 1 | 2019 | 378 | 0.04 | Why? |
| Oligopeptides | 1 | 2020 | 576 | 0.04 | Why? |
| Oxazines | 1 | 2018 | 279 | 0.04 | Why? |
| Tokyo | 1 | 2019 | 645 | 0.04 | Why? |
| Proteolysis | 1 | 2020 | 751 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.04 | Why? |
| Hepacivirus | 2 | 2019 | 1509 | 0.04 | Why? |
| Recombinant Fusion Proteins | 1 | 2020 | 919 | 0.04 | Why? |
| Cell Line | 2 | 2021 | 12040 | 0.04 | Why? |
| Dose-Response Relationship, Immunologic | 1 | 2017 | 593 | 0.04 | Why? |
| Cyclopropanes | 1 | 2017 | 332 | 0.04 | Why? |
| Piperazines | 1 | 2018 | 445 | 0.04 | Why? |
| Hepatitis A | 1 | 2017 | 140 | 0.04 | Why? |
| Disease Outbreaks | 2 | 2020 | 27595 | 0.04 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.04 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.03 | Why? |
| Viral Load | 3 | 2021 | 15850 | 0.03 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 8811 | 0.03 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.03 | Why? |
| Amino Acid Substitution | 1 | 2021 | 1706 | 0.03 | Why? |
| Catalytic Domain | 1 | 2020 | 1757 | 0.03 | Why? |
| Male | 13 | 2020 | 367725 | 0.03 | Why? |
| Tinidazole | 1 | 2012 | 9 | 0.03 | Why? |
| Liver Abscess, Amebic | 1 | 2012 | 8 | 0.03 | Why? |
| Virus Shedding | 2 | 2020 | 5834 | 0.03 | Why? |
| Parasitology | 1 | 2012 | 17 | 0.03 | Why? |
| Molecular Epidemiology | 1 | 2019 | 1638 | 0.03 | Why? |
| Metronidazole | 1 | 2012 | 59 | 0.03 | Why? |
| Pyridones | 1 | 2018 | 738 | 0.03 | Why? |
| Sexual Partners | 1 | 2017 | 612 | 0.03 | Why? |
| Antiprotozoal Agents | 1 | 2012 | 83 | 0.03 | Why? |
| Dyslipidemias | 1 | 2019 | 791 | 0.03 | Why? |
| Counseling | 1 | 2017 | 747 | 0.03 | Why? |
| Immunoglobulin G | 3 | 2021 | 21571 | 0.03 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.03 | Why? |
| Darunavir | 1 | 2014 | 477 | 0.03 | Why? |
| Mice, Transgenic | 1 | 2018 | 2739 | 0.03 | Why? |
| Killer Cells, Natural | 1 | 2020 | 2093 | 0.03 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.03 | Why? |
| Sequence Homology | 1 | 2011 | 448 | 0.03 | Why? |
| Pandemics | 5 | 2020 | 389249 | 0.03 | Why? |
| Protein Conformation | 1 | 2020 | 4386 | 0.02 | Why? |
| Young Adult | 4 | 2017 | 93724 | 0.02 | Why? |
| Hong Kong | 1 | 2019 | 3361 | 0.02 | Why? |
| Up-Regulation | 1 | 2018 | 2249 | 0.02 | Why? |
| Vaccines, Inactivated | 1 | 2017 | 1562 | 0.02 | Why? |
| Microscopy | 1 | 2012 | 414 | 0.02 | Why? |
| Immunization, Secondary | 1 | 2017 | 1649 | 0.02 | Why? |
| Drug Evaluation, Preclinical | 1 | 2020 | 3347 | 0.02 | Why? |
| Sexual Behavior | 1 | 2017 | 1322 | 0.02 | Why? |
| Middle Aged | 7 | 2021 | 270681 | 0.02 | Why? |
| Treatment Outcome | 3 | 2020 | 51732 | 0.02 | Why? |
| Drug Combinations | 1 | 2016 | 3852 | 0.02 | Why? |
| Hepatitis B Antibodies | 1 | 2007 | 142 | 0.02 | Why? |
| Japan | 1 | 2020 | 6653 | 0.02 | Why? |
| Molecular Sequence Data | 1 | 2011 | 3198 | 0.02 | Why? |
| Acute Disease | 1 | 2019 | 6029 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 7868 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.02 | Why? |
| Follow-Up Studies | 2 | 2017 | 17020 | 0.02 | Why? |
| Female | 7 | 2020 | 380317 | 0.02 | Why? |
| Cluster Analysis | 1 | 2011 | 3001 | 0.02 | Why? |
| Adolescent | 2 | 2017 | 86841 | 0.02 | Why? |
| China | 2 | 2020 | 50654 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2011 | 2830 | 0.02 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.01 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.01 | Why? |
| Antibodies, Neutralizing | 2 | 2021 | 25288 | 0.01 | Why? |
| Risk Factors | 3 | 2019 | 71621 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2021 | 53120 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
| Travel | 1 | 2020 | 7220 | 0.01 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.01 | Why? |
| Incidence | 2 | 2014 | 25622 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.01 | Why? |
| Prospective Studies | 2 | 2017 | 43301 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.01 | Why? |
| Survival Analysis | 1 | 2012 | 7592 | 0.01 | Why? |
| Cytokines | 1 | 2020 | 15010 | 0.01 | Why? |
| Mice | 1 | 2018 | 21357 | 0.01 | Why? |
| Aged | 2 | 2020 | 215776 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2008 | 88759 | 0.01 | Why? |
| Polymerase Chain Reaction | 1 | 2012 | 6740 | 0.01 | Why? |
| DNA, Viral | 1 | 2007 | 2521 | 0.01 | Why? |
| Coinfection | 1 | 2016 | 6820 | 0.01 | Why? |
| Viral Nonstructural Proteins | 1 | 2011 | 4810 | 0.01 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.01 | Why? |
| Serologic Tests | 1 | 2007 | 4359 | 0.01 | Why? |
| Case-Control Studies | 1 | 2011 | 17671 | 0.01 | Why? |
| Vaccination | 1 | 2017 | 19050 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.01 | Why? |
| Cohort Studies | 1 | 2011 | 36005 | 0.01 | Why? |
| Biomarkers | 1 | 2007 | 23361 | 0.00 | Why? |
| Retrospective Studies | 1 | 2014 | 105322 | 0.00 | Why? |
Chang's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(195)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(119)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_